Qsemble Capital Management LP Sells 3,804 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Qsemble Capital Management LP trimmed its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 14.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,693 shares of the company’s stock after selling 3,804 shares during the quarter. Qsemble Capital Management LP’s holdings in Hims & Hers Health were worth $418,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its position in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC lifted its position in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the period. CWM LLC lifted its position in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the period. Van ECK Associates Corp bought a new position in Hims & Hers Health in the second quarter worth $111,000. Finally, Amalgamated Bank lifted its position in Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares during the period. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Stock Down 1.1 %

Hims & Hers Health stock opened at $30.35 on Thursday. The stock has a market capitalization of $6.63 billion, a price-to-earnings ratio of 68.98 and a beta of 1.06. Hims & Hers Health, Inc. has a 12-month low of $8.09 and a 12-month high of $35.02. The stock has a 50-day simple moving average of $21.14 and a 200 day simple moving average of $19.57.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.04) EPS. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total value of $38,593.50. Following the completion of the sale, the insider now directly owns 176,952 shares of the company’s stock, valued at $2,919,708. This represents a 1.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. This trade represents a 84.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,153,519 shares of company stock valued at $24,486,721. 17.71% of the stock is currently owned by insiders.

Analysts Set New Price Targets

HIMS has been the subject of a number of analyst reports. Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. TD Cowen reissued a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Piper Sandler reissued a “neutral” rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Finally, Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price objective for the company from $32.00 to $18.00 in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $20.71.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.